Patients with HER2-positive breast cancer tumors 3 cm or smaller and negative nodes received paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by trastuzumab for 9 months. Here, ERBB2 is linked to breast carcinoma.